JP2011530309A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011530309A5 JP2011530309A5 JP2011523001A JP2011523001A JP2011530309A5 JP 2011530309 A5 JP2011530309 A5 JP 2011530309A5 JP 2011523001 A JP2011523001 A JP 2011523001A JP 2011523001 A JP2011523001 A JP 2011523001A JP 2011530309 A5 JP2011530309 A5 JP 2011530309A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- mammal
- polypeptide
- protein
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 4
- 230000001939 inductive effect Effects 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 239000000969 carrier Substances 0.000 claims 2
- 230000028993 immune response Effects 0.000 claims 2
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000003612 virological Effects 0.000 claims 1
Claims (9)
- 図２１または図２２に示す少なくとも１つのアミノ酸配列を含む、ポリペプチドまたはタンパク質。
- 請求項１に記載のポリペプチドまたはタンパク質をコードする核酸。
- 図２２に示す少なくとも１つのヌクレオチド配列を含む核酸。
- 請求項２または３に記載の核酸を含むベクター。
- ベクターがウイルスベクターである、請求項４に記載のベクター。
- 請求項１に記載の少なくとも１つのポリペプチドまたはタンパク質およびキャリヤーを含む組成物。
- 請求項２または３に記載の少なくとも１つの核酸およびキャリヤーを含む組成物。
- 哺乳動物において免疫応答を誘導する方法であって、哺乳動物にその誘導を生じるのに十分な量の請求項１に記載の少なくとも１つのポリペプチドまたはタンパク質を投与することを含む方法。
- 哺乳動物において免疫応答を誘導する方法であって、その誘導を生じるのに十分な量の請求項２または３に記載の少なくとも１つの核酸をその哺乳動物に投与することを含む方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/192,015 | 2008-08-14 | ||
| US12/192,015 US7951377B2 (en) | 2005-08-23 | 2008-08-14 | Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens |
| PCT/US2009/004664 WO2010019262A2 (en) | 2008-08-14 | 2009-08-14 | Polyvalent vaccine |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014120307A Division JP2014207910A (ja) | 2008-08-14 | 2014-06-11 | 多価ワクチン |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011530309A JP2011530309A (ja) | 2011-12-22 |
| JP2011530309A5 true JP2011530309A5 (ja) | 2012-10-04 |
Family
ID=41669535
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011523001A Pending JP2011530309A (ja) | 2008-08-14 | 2009-08-14 | 多価ワクチン |
| JP2014120307A Pending JP2014207910A (ja) | 2008-08-14 | 2014-06-11 | 多価ワクチン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014120307A Pending JP2014207910A (ja) | 2008-08-14 | 2014-06-11 | 多価ワクチン |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US7951377B2 (ja) |
| EP (2) | EP3178842B1 (ja) |
| JP (2) | JP2011530309A (ja) |
| CN (1) | CN102177175A (ja) |
| AU (1) | AU2009282442B2 (ja) |
| BR (1) | BRPI0917205A2 (ja) |
| CA (1) | CA2733898C (ja) |
| IL (1) | IL211184B (ja) |
| WO (1) | WO2010019262A2 (ja) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101969996A (zh) * | 2005-08-23 | 2011-02-09 | 加利福尼亚大学董事会 | 多价疫苗 |
| US7951377B2 (en) | 2005-08-23 | 2011-05-31 | Los Alamos National Security, Llc | Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens |
| BRPI0921588B1 (pt) | 2008-11-18 | 2021-12-28 | Beth Israel Deaconess Medical Center | Vacina compreendendo um polipeptídeo viral e seu método de preparação, kit e uso do polipeptídeo viral |
| WO2013006688A2 (en) | 2011-07-05 | 2013-01-10 | Duke University | N-terminal deleted gp120 immunogens |
| CA2850745C (en) * | 2011-10-03 | 2022-12-13 | Duke University | Vaccine |
| MX2015007584A (es) | 2012-12-13 | 2016-03-15 | Baylor Res Inst At Dallas | Triheptanoina para el tratamiento de la deficiencia del transportador de glucosa 1. |
| US10010606B2 (en) * | 2013-09-30 | 2018-07-03 | Los Alamos National Security, Llc | Mosaic conserved region HIV immunogenic polypeptides |
| US9920305B2 (en) | 2013-10-16 | 2018-03-20 | New England Biolabs, Inc. | Reverse transcriptase with enhanced properties |
| EP3119890A4 (en) | 2014-03-19 | 2017-12-27 | Duke University | Swarm immunization with envelopes from ch505 |
| AU2015236147A1 (en) * | 2014-03-25 | 2016-10-13 | Duke University | Mosaic HIV-1 sequences and uses thereof |
| EP3126502A4 (en) | 2014-03-31 | 2018-01-17 | Duke University | Compositions comprising ch848 envelopes and uses thereof |
| EP3197488A4 (en) | 2014-09-28 | 2018-03-21 | Duke University | Compositions comprising ch505 envelopes, and trimers |
| WO2017151801A1 (en) | 2016-03-01 | 2017-09-08 | Duke University | Compositions comprising hiv envelopes to induce ch235 lineage antibodies |
| US11318197B2 (en) | 2016-03-03 | 2022-05-03 | Duke University | Compositions and methods for inducing HIV-1 antibodies |
| US11246920B2 (en) | 2016-03-03 | 2022-02-15 | Duke University | Compositions and methods for inducing HIV-1 antibodies |
| CA3039089A1 (en) | 2016-10-03 | 2018-04-12 | Duke University | Methods to identify immunogens by targeting improbable mutations |
| EP3526236A4 (en) * | 2016-10-17 | 2020-06-03 | Beth Israel Deaconess Medical Center, Inc. | SIGNATURE-BASED HUMAN IMMUNODEFICIENCY VIRUS VACCINES (ENV) CONTAINING SIGNS AND METHODS OF USE THEREOF |
| EP3630174A4 (en) | 2017-05-25 | 2021-07-07 | Duke University | COMPOSITIONS INCLUDING MODIFIED HIV ENVELOPES |
| CA3145791A1 (en) | 2019-07-16 | 2021-01-21 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6139843A (en) * | 1991-04-02 | 2000-10-31 | Albert Einstein College Of Medicine Of Yeshiva University | Peptide compositions for the treatment of HIV |
| US6541011B2 (en) * | 1998-02-11 | 2003-04-01 | Maxygen, Inc. | Antigen library immunization |
| US6503753B1 (en) * | 1998-02-13 | 2003-01-07 | Adan Rios | Method for the development of an HIV vaccine |
| US20030180314A1 (en) * | 1998-07-10 | 2003-09-25 | Degroot Anne | Immunogenic, cross-clade, HIV peptides |
| US7935805B1 (en) * | 1998-12-31 | 2011-05-03 | Novartis Vaccines & Diagnostics, Inc | Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof |
| US6710173B1 (en) * | 1999-06-25 | 2004-03-23 | Progenics Pharmaceuticals, Inc. | Stabilized viral envelope proteins and uses thereof |
| US7655774B2 (en) * | 2000-02-18 | 2010-02-02 | University Of Washington | Ancestral and COT viral sequences, proteins and immunogenic compositions |
| US20040115621A1 (en) * | 2000-02-18 | 2004-06-17 | Allen Rodrigo | Ancestral viruses and vaccines |
| US6733993B2 (en) * | 2000-09-15 | 2004-05-11 | Merck & Co., Inc. | Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications |
| US7195768B2 (en) | 2001-11-07 | 2007-03-27 | Duke University | Polyvalent immunogen |
| AU2002363436A1 (en) * | 2001-11-07 | 2003-05-19 | Duke University | Polyvalent immunogen of hiv |
| ATE520708T1 (de) * | 2003-03-28 | 2011-09-15 | Us Gov Health & Human Serv | Immunogenetische hiv-1 multi-klade, multivalente konstrukte und deren verwendung |
| CA2520768A1 (en) * | 2003-03-28 | 2005-02-10 | Idm Pharma, Inc. | Methods of identifying optimal variants of peptide epitopes |
| CA2539068C (en) * | 2003-09-15 | 2013-07-23 | The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services | Hiv vaccines based on env of multiple clades of hiv |
| CA2918585C (en) * | 2003-09-17 | 2019-05-21 | Duke University | Consensus/ancestral immunogens |
| WO2005035555A1 (en) * | 2003-10-10 | 2005-04-21 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv/siv env chimeras that promote trimerization and maintain targets of neutralizing antibodies |
| US7951377B2 (en) | 2005-08-23 | 2011-05-31 | Los Alamos National Security, Llc | Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens |
| CN101969996A (zh) | 2005-08-23 | 2011-02-09 | 加利福尼亚大学董事会 | 多价疫苗 |
| EP1954309A2 (en) | 2005-10-17 | 2008-08-13 | Novartis AG | Multiclade hiv vaccines |
| US20130273103A1 (en) | 2010-09-28 | 2013-10-17 | Los Alamos National Security, Llc | Polyvalent immunogen |
-
2008
- 2008-08-14 US US12/192,015 patent/US7951377B2/en not_active Expired - Fee Related
-
2009
- 2009-08-14 JP JP2011523001A patent/JP2011530309A/ja active Pending
- 2009-08-14 CN CN2009801404211A patent/CN102177175A/zh active Pending
- 2009-08-14 BR BRPI0917205A patent/BRPI0917205A2/pt not_active IP Right Cessation
- 2009-08-14 EP EP16184203.4A patent/EP3178842B1/en active Active
- 2009-08-14 EP EP09806982A patent/EP2318430A4/en not_active Withdrawn
- 2009-08-14 WO PCT/US2009/004664 patent/WO2010019262A2/en active Application Filing
- 2009-08-14 CA CA2733898A patent/CA2733898C/en not_active Expired - Fee Related
- 2009-08-14 AU AU2009282442A patent/AU2009282442B2/en not_active Ceased
- 2009-08-14 US US12/737,761 patent/US9044445B2/en not_active Expired - Fee Related
-
2011
- 2011-02-10 IL IL211184A patent/IL211184B/en active IP Right Grant
- 2011-04-26 US US13/094,734 patent/US9011873B2/en not_active Expired - Fee Related
-
2014
- 2014-06-11 JP JP2014120307A patent/JP2014207910A/ja active Pending
-
2015
- 2015-04-17 US US14/689,995 patent/US9821053B2/en active Active
- 2015-05-29 US US14/726,373 patent/US9844590B2/en active Active
-
2017
- 2017-12-15 US US15/843,233 patent/US20180185471A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011530309A5 (ja) | ||
| JP2011136997A5 (ja) | ||
| JP2014513951A5 (ja) | ||
| RU2016146198A (ru) | Терапевтические dll4-связывающие белки | |
| JP2010227108A5 (ja) | ||
| WO2006063101A3 (en) | Vaccines for the rapid response to pandemic avian influenza | |
| JP2013539361A5 (ja) | ||
| EP4303232A3 (en) | Chimeric antigen receptor and methods of use thereof | |
| JP2014012688A5 (ja) | ||
| JP2015524422A5 (ja) | ||
| WO2010138263A3 (en) | Novel aav 's and uses thereof | |
| WO2007147529A3 (en) | Recombinant viral vaccine | |
| HRP20230259T1 (hr) | Mutant polipeptida faktora ix, njegove primjene i postupak za njegovu proizvodnju | |
| JP2010088434A5 (ja) | ||
| JP2011528896A5 (ja) | ||
| MX346475B (es) | Peptidos inmunogenicos monomericos y multimericos. | |
| WO2011008956A3 (en) | Mammalian genes involved in infection | |
| PL2672992T3 (pl) | Cząsteczka kwasu nukleinowego kodująca białko rdzeniowe wirusa zapalenia wątroby typu B i szczepionka je zawierająca | |
| JP2019530462A5 (ja) | ||
| WO2010134939A3 (en) | Mammalian genes involved in infection | |
| WO2013052859A3 (en) | Adenoviral vector-based respiratory syncytial virus (rsv) vaccine | |
| HRP20201945T1 (hr) | Postupak proizvodnje gonadotropina | |
| JP2014525439A5 (ja) | ||
| WO2010039778A3 (en) | Mammalian genes involved in infection | |
| MX2015009867A (es) | Mutantes del factor x. |